Granules India Limited — Investor Meet, 23-01-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Granules India reported robust Q3 FY26 financial results. Revenue climbed 22% YoY (7% QoQ) to ₹1,387.9 Cr. EBITDA jumped 34% YoY (11% QoQ) to ₹308.1 Cr, achieving margins of 22.2%, despite a ₹24.8 Cr EBITDA loss from Ascelis Peptides. PAT rose 28% YoY (15% QoQ) to ₹150.2 Cr. Growth was primarily driven by Finished Dosages in North America and Europe, aided by a favorable product mix. The company maintains #1 market share in 25% of its US portfolio. Key operational achievements include ANVISA GMP approval and zero FDA observations. R&D spend was ₹68.9 Cr (5.0% of sales), supporting a strategic shift towards complex generics. Sentiment remains positive on sustained performance and strategic initiatives.